PITTSBURGH--(BUSINESS WIRE)--RedPath Integrated Pathology, Inc. (“RedPath”), a cancer molecular diagnostics company headquartered in Pittsburgh, PA, announced today that it has terminated the Combination Agreement dated as of April 26, 2010, as amended by Extension Agreement dated as of August 1, 2010 (collectively, the “Combination Agreement”) entered by and among ExonHit Therapeutics S.A. (“EHT”), ExonHit U.S. Holding, Inc., ExonHit Acquisition Corp. and RedPath Integrated Pathology, Inc. (the “Company”), certain stockholders of the Company and Brian Murphy as Stockholders’ Representative (“Stockholders’ Representative”). RedPath’s Board of Directors agreed that the firm would be better served to begin seeking alternative strategic and financial options.
